News coverage about NuVasive (NASDAQ:NUVA) has trended somewhat positive this week, Accern Sentiment Analysis reports. The research firm identifies positive and negative news coverage by analyzing more than twenty million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. NuVasive earned a coverage optimism score of 0.14 on Accern’s scale. Accern also gave news stories about the medical device company an impact score of 46.8446180547279 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the near term.
These are some of the media headlines that may have impacted Accern Sentiment’s scoring:
NuVasive (NASDAQ NUVA) opened at $51.04 on Wednesday. The firm has a market capitalization of $2,560.00, a PE ratio of 44.00, a price-to-earnings-growth ratio of 1.30 and a beta of 0.50. The company has a debt-to-equity ratio of 0.73, a current ratio of 3.48 and a quick ratio of 1.94. NuVasive has a 52-week low of $44.62 and a 52-week high of $81.68.
NuVasive (NASDAQ:NUVA) last released its earnings results on Monday, February 26th. The medical device company reported $0.56 earnings per share for the quarter, meeting the consensus estimate of $0.56. The company had revenue of $271.70 million during the quarter, compared to the consensus estimate of $272.11 million. NuVasive had a return on equity of 13.40% and a net margin of 8.06%. NuVasive’s revenue was up .2% compared to the same quarter last year. During the same period in the previous year, the company posted $0.53 EPS. equities research analysts anticipate that NuVasive will post 2.46 earnings per share for the current year.
Several research analysts have recently commented on NUVA shares. Royal Bank of Canada reduced their price target on NuVasive from $75.00 to $70.00 and set an “outperform” rating on the stock in a report on Friday, November 10th. BTIG Research set a $74.00 price objective on shares of NuVasive and gave the company a “buy” rating in a report on Wednesday, December 13th. BMO Capital Markets restated a “buy” rating and issued a $70.00 price objective on shares of NuVasive in a report on Thursday, December 14th. BidaskClub upgraded shares of NuVasive from a “sell” rating to a “hold” rating in a report on Friday, December 15th. Finally, Zacks Investment Research upgraded shares of NuVasive from a “sell” rating to a “hold” rating in a report on Tuesday, December 19th. Two equities research analysts have rated the stock with a sell rating, five have issued a hold rating and twelve have issued a buy rating to the company. NuVasive has an average rating of “Buy” and a consensus price target of $68.19.
In other news, CEO Gregory T. Lucier bought 6,000 shares of the company’s stock in a transaction on Thursday, March 1st. The stock was bought at an average cost of $48.57 per share, with a total value of $291,420.00. The acquisition was disclosed in a legal filing with the SEC, which is available through this link. Insiders own 1.20% of the company’s stock.
NuVasive Company Profile
Nuvasive, Inc is a medical device company. The Company focuses on developing minimally-disruptive surgical products and procedurally-integrated solutions for the spine surgery. Its product portfolio focuses on applications for spine fusion surgery, including biologics used to aid in the spinal fusion process.